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1. Introduction 
Since the first successful kidney transplantation in 1954 between Identical twins, a new 
modality to treat patients with terminal kidney insufficiency was born. Although the results 
in the first decades were modest, continuous development has characterized this captivating 
field. A major advance was the introduction of the new immunosuppressant cyclosporine A 
in the early 1980s. The fundament of its success was the aptitude to improve kidney graft 
survival significantly over the first year, and calcineurin inhibitors are the cornerstone of 
immunosuppression even in the present decade. 
Chronic allograft nephropathy is a histopathological diagnosis used to denote features of 
chronic interstitial fibrosis and tubular atrophy within the renal allograft. It remains the 
most common cause of graft dysfunction and loss after renal transplantation. 
The term Chronic allograft nephropathy was proposed in 1991, and it replaced the 
previously used term “chronic rejection”. The intention was to unify chronic histological 
changes seen under light microscopy, such us interstitial fibrosis, tubular atrophy, 
transplant glomerulopathy and vasculopathy. The pathophysiology behind each of these 
features may nevertheless be different. The processes involved are approached by dividing 
them roughly into immunological and non-immunological factors, although they may be 
interrelated.  
In this chapter we will discuss the histological features, the pathogenesis, the different 
etiologies and the therapeutic possibilities in cases of chronic allograft nephropathy. 
2. Epidemiology of chronic allograft nephropathy 
Prevalence of chronic allograft nephropathy at 2 years was reported in a prospective 
multicenter trial that compared cyclosporine against Tacrolimus (Solez et al., 1998), in which 
72.3 % and 62.0 % of biopsies exhibited CAN, respectively. There was no difference in 
chronic histology between the therapeutic arms, but CAN at 2 years was associated with 
older donor age, early acute rejection, and episodes of acute CNI nephrotoxicity. Functional 
studies unfortunately underestimate significantly the incidence of histological graft injury. 
One study found that 94 % of grafts has histological evidence of interstitial fibrosis and 
tubular atrophy at 1 year (Nankivell et al., 2003). This same study found that much of the 
progressive chronic damage was related to Calcineurin inhibitors, even though the levels of 
these drugs had been maintained well within the defined target range.  
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3. Histopathology of chronic allograft nephropathy 
Previously, chronic allograft rejection was considered the main aetiological factor for 
chronic graft loss, as features of cellular inflammatory immune infiltrates, identified on 
kidney biopsies, were suggestive of injury from immunological changes within the graft. 
This classification changed with the implementation of the Banff 97 working classification of 
renal allograft pathology criteria, which integrated features of the Chronic Allograft 
Damage Index (Racusen et al., 1999) and Cooperative Clinical Trials in Transplantation 
systems (Isonemi et al., 1994). This led to the standardization and semiquantification of 
these lesions. Then, the term chronic allograft nephropathy replaced chronic allograft 
rejection. 
The histological features that define chronic allograft nephropathy in the kidney transplant 
allograft include interstitial fibrosis and tubular atrophy, as mentioned above, as well as 
features of glomerulosclerosis with an aspect of double contours in the glomerular basement 
membrane, arteriolar hyalinosis and arteriolosclerosis (Fig 1) (Nankivell et Chapman, 2006).  
 
 
Fig. 1. Histological manifestations of chronic allograft nephropathy 
Chronic allograft nephropathy is graded as mild, moderate or severe based on the severity 
of chronic interstitial fibrosis and tubular atrophy and the area of cortex affected in the 
biopsy specimen. Interstitial fibrosis, denoted as ci, is scored by the area fibrosed and ranges 
from mild (ci1 6–25%) to severe (ci3 >50%). Tubular atrophy refers to the loss of tubular 
height and increased luminal size of the tubules and is denoted as ct (ct0–ct3). Tubular 
atrophy and interstitial fibrosis are often nonspecific by themselves (Table 1).  
Chronic transplant glomerulopathy refers to the thickening of the glomeruli and is 
quantified by the percentage of glomeruli developing “double contours” of peripheral 
capillary loops and is denoted as cg (cg0–cg3). Arteriolar hyalinosis, as suggested by the 
term, denotes thickening of arterioles within the kidney based on the amount of periodic-
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acid-Schiff-positive hyalinosis and is denoted as ah (ah0–ah3), often implying calcineurin 
inhibitor nephropathy. More in-depth quantification of all of these criteria is readily 
available (Racusen et al., 1999). 
 
 
Table 1. Histologic revisted criteria of chronic allograft nephropathy 
The addition of C4d staining to the Banff criteria in 2003 has allowed for the helpful 
diagnosis of chronic antibodymediated rejection. C4d is a positive marker of complement 
activation, implying the presence of antidonor antibodies and hence antibody-mediated 
rejection. C4d is released on binding to antibody. These antibodies bind to endothelial cells 
in glomerular and peritubular capillaries, suggesting antibody deposition (Fuecht et al., 
1991, Nickeleitt et al., 2002) and prompting the clinician to request donor-specific antibody 
testing. C4d staining is regarded as positive or negative, and its position within the biopsy is 
recorded and graded by type, as acute tubular necrosis-like, capillary or arterial (Racusen et 
al., 2003). C4d has a role in acute rejection, early unexplained primary graft non function 
and chronic dysfunction where transplant glomerulopathy is present (Nickeleitt et al., 2002). 
The evidence for chronic allograft nephropathy as the leading cause for progressive renal 
failure and graft loss is supported by both transplant registry and protocol biopsy data. 
Graft loss secondary to the progressive development of chronic allograft nephropathy has 
consistently been recorded within Australian–New Zealand (ANZDATA) transplantation 
registries (Chang et al., 2007). Although histological confirmation of chronic allograft 
nephropathy by biopsy is variable, reports from all databases show progressive transplant 
loss attributable to CAN continuing to the present day despite improved changes to 
immunosuppression regimens. Cohort studies using protocol biopsies performed from day 
of transplant to 10 years posttransplantation consistently demonstrate the evolution and 
progression of CAN (Fernando et al., 2004, Nankivell et al., 2003, 2004c, Schwarz et al, 2005). 
Larger studies have helped identify aetiological factors involved in chronic graft injury. 
In particular, the 10-year protocol biopsy study on adult patients with kidney–pancreas 
transplants defined the occurrence of severe rejection, of subclinical rejection and in some 
cases true chronic rejection, as evidenced by tubulointerstitial damage, with increasing 
evidence of progressive nephropathy from calcineurin inhibitors. Histological lesions of 
grade 1 chronic allograft nephropathy present in up to 94.2% of adult patients at 1 year 
posttransplant (Nankivell et al., 2003, 2004c), and grades   progressively worsen up to 10 
years.  
4. Pathogenesis of chronic allograft nephropathy 
The pathogenesis of chronic allograft nephropathy is still not fully elucidated, although 
several theories have been suggested (Häyry et al., 1993, Halloran et al., 1999, Paul et al., 
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1999, Joosten et al., 2004). Chronic allograft nephropathy is thought to initiate from a series 
of challenges to the allograft. Injury to the graft begins even before the effect of the 
alloresponse: donor brain death, warm ischemia, cold ischemia, and ischemia/reperfusion 
injury all result in increased immunogenicity in the graft, causing increased inflammatory 
alloresponse after the revascularization of the allograft. Series of injuries continues during 
the first weeks after transplantation; acute tubular necrosis, acute rejection episodes, 
calcineurin inhibitors nephrotoxicity, and infections in the graft, among others, contribute to 
the injury of the transplanted kidney. All this occurs against the background of foreign 
MHC antigens and often in a kidney from an older donor with some extent of age associated 
changes and limited capacity of restoration from injury.  
Renal injury is thought to result in an inflammatory response; recipient lymphocytes and 
monocytes enter the graft and produce cytokines, which stimulate inflammatory and 
mesenchymal cells to produce excess growth factors, resulting in proliferation of 
myofibroblasts and smooth muscle cells in the vascular wall and increased of collagen 
synthesis in fibroblasts. This process is thought to lead to scar formation; excess interstitial 
fibrosis, tubular atrophy and vascular intimal thickening represent the stereotypic 
histopathological picture seen in endstage renal diseases. 
 
 
Fig. 2. Major risk factors of chronic allograft nephropathy 
Whether the initial injury in the graft occurs in the vascular wall, resulting in the 
proliferation of the vascular wall and narrowing of the lumen, followed by tubulointerstitial 
lesions due to growth factor response and partly ischemia (Häyry et al., 1993), or whether 
the initial event is tubular cell injury, resulting in growth factor response, tubular atrophy, 
interstitial fibrosis, and finally vascular narrowing, is still under discussion (Paul et al., 
1999). Nankivell et al. (2003) support the hypothesis that interstitial fibrosis and tubular 
atrophy were the first manifestations of chronic allograft nephropathy and preceded 
vasculopathic changes. Most of the histopathological changes of chronic allograft 
nephropathy are also seen in the aging kidney. This fact and knowledge of the limited cell 
cycle capacity has led to the theory that cellular or tissue senescence might play a role in the 
pathogenesis of chronic allograft nephropathy (Halloran et al., 1999). 
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Continuous injury to an aging graft may result in exhaustion of the replicative cells and 
inability to repair injury and remodel the tissue in an adequate way. This is thought to lead 
to the histopathological lesions seen in chronic allograft nephropathy. 
5. Diagnosis of chronic allograft nephropathy 
Clinically, chronic allograft nephropathy is characterized by a slow but variable loss of 
function, starting 3 months after implantation, often in combination with proteinuria 
generally in the non nephritic range and hypertension (Paul et al., 1999). 
The progressive decline in renal function measured by increasing serum creatinine, or the 
development of overt proteinuria, is often the first indication alerting the clinician to the 
presence of chronic allograft nephropathy. Evaluation of large registry data, however, has 
shown that serum creatinine has limited predictive value for subsequent graft loss (Kaplan 
et al., 2003). A single reference range for serum creatinine can be misleading and often 
underestimates the deterioration of renal function, especially at glomerular filtration rate 
between 30 and 70 mL/min (Levey et al., 1999). If clinicians wait until their individual 
patients start showing rising creatinine levels, then a considerable amount of damage will 
already have been done and it may be too late for successful intervention (Chapman et al., 
2005).  
6. Risk factors of chronic allograft nephropathy 
6.1 Immune-dependent factors 
6.1.1 HLA mismatches 
HLA antigens present in the donor but absent in the recipient are counted as HLA-
mismatches. HLA-A, -B and –DR mismatches have been associated with poor graft survival. 
Although organ allocation relies on several non-immunological and logistic factors, a close 
HLA match is desirable. It was clearly demonstrated that the greater the number of 
mismatches, the poorer the graft survival at 5 years of follow-up (Opelz et al. 1999) The 
importance of HLA-mismatch in the era of modern immunosuppression (i.e. tacrolimus, 
mycophenolate mophetil, induction therapies) was evaluated in the largest European study, 
where the results of two eras: 1985–1994 and 1995–2004, were compared. A total of 135,970 
cadaver kidney transplants were followed up for 5 years. Although the survival rates 
improved over the years, HLA mismatches still had a clear impact. A multiregression 
analysis of factors contributing to graft survival revealed that the impact of HLA-
mismatches on graft survival was equally strong in the two decades compared (Opelz  
Döhler 2007). 
6.1.2 Sensitization 
The main routes of sensitization are blood transfusion, pregnancy and transplantation.  
Alloantibodies were first implicated in chronic rejection of human allografts (Russel 1970) 
with the occurrence of chronic allograft arteriopathy only in patients who developed de 
novo antidonor antibodies (human leukocyte antigen (HLA)). Terasaki et al. (2007) detected 
an association of circulating HLA antibodies with an increased risk of long-term graft loss. 
Halloran et et al. (1990) showed that acute renal allograft rejection in patients with donor-
specific anticlass 1 HLA antibodies had distinct pathological features. An advance finding 
was the demonstration of the complement fragment C4d in peritubular capillaries (PCT) in 
www.intechopen.com
 
After the Kidney Transplant – The Patients and Their Allograft 
 
302 
patients with acute rejection (Feucht et al., 1991). This was tied to circulating donor-specific 
antibodies and graft pathology by Collins et al., (1999), and confirmed by many others, 
leading to the introduction of the diagnosis “acute antibody-mediated rejection” in the 
BANFF classification. Mauyyedi et al. (2002) then connected the dots and discovered that 
glomerulopathy or arteriopathy was liked to C4d deposition in peritubular capillaries and 
donor-specific alloantibody. For this condition, a new term was proposed with “chronic 
humoral rejection”. Several groups had confirmed these findings and it’s clear that about 50 
% of patients with transplant glomerulopathy or arteriopathy have C4d deposition in 
peritubular capillaries (Sis et al., 2007, Calvin et al., 2007).  
6.1.3 Chronic humoral rejection 
In 2005, the Banff consensus conference added a new category “chronic active antibody-
mediated rejection” to its classification with the criteria given in table 2 (Solez et al., 2007). 
 
Morphological features 
     Duplication of glomerular basement membrane (cg1-3) 
     Multilaminated PTC basement membrane 
     Arterial intimal fibrosis without elastosis 
     Interstitial fibrosis with tubular atrophy with or without PTC loss  
Diffuse C4d positivity along PTC 
Presence of donor-specific antibody 
Abbreviation: PTC, perittubular capillary 
Table 2. Banff criteria for chronic antibody-mediated rejection 
Recent studies have indicated that chronic humoral rejection is common in unselected 
indication biopsies, found in one 10-year series in 9.3 % of 771 cases (Farris, 2009). The onset of 
chronic humoral rejection is typically late, after the first year, and the prevalence rises 
progressively to about 20 % in the fifth year. Proteinuria is common but not invariable (50 % 
have > 1 g per day proteinuria). Renal function is often abnormal, but can remain stable for 
considerable time periods (years) (Kieran et al., 2009).The strongest risk factor identified to 
date is the existence of pretransplant donor-specific antibodies, but most cases occur in 
patients without a history of presensitization or even an episode of acute humoral rejection. 
Serologically, the most interesting aspect of chronic humoral rejection is the strong association 
with class II DSA (Gloor et al., 2007) which is not a characteristic of acute humoral rejection.  
The major features of chronic humoral rejection are duplication of the glomerular basement 
membrane (“transplant glomerulopathy”), multilamination of peritubular capillaries 
basement, mononuclear cells in glomeruli and peritubular capillaries, and loss of normal 
glomerular capillary endothelial fenestrations (Colvin et al., 2006). In addition to 
multilamination of basement membranes, loss of peritubular capillaries has been 
demonstrated in patients with chronic graft injury and this correlates inversely with serum 
creatinine (Ishii et al., 2005). It is possible that the loss of capillaries is related to endothelial-
mesenchymal transition (Zeisberg et al., 2007).  
6.1.4 Acute rejection 
Historically, acute rejection episodes that are severe, recurrent, or that occur late have been 
associated with inferior outcomes. The strong correlation between late acute rejection and 
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chronic allograft rejection, as well as late graft loss, has been reported consistently 
(Nankivell et al., 2001, Sijpkens et al., 2003). The risk of graft loss is different for acute 
rejections that are functional reversible on treatment compared with those with functional 
deterioration (Meier-Kreische et al., 2004). In the mean time however, higher risk donors 
and recipients have also been transplanted in more recent times. An impaired ability to 
tissue restoration in these kidneys, as has been described for acute cellular or Banff grade I 
rejection in kidneys from older donors, may at least partly explain the observed lack of 
functional reversibility (de Fijter et al., 2001).  
6.1.5 Subclinical rejection 
The term subclinical rejection refers to allografts with stable renal function that display an 
interstitial infiltrate and tubulitis.  
There is increasing evidence that subclinical rejection may represent an important factor in 
predicting early graft loss (Nankivell et al., 2004b, Veronese et al., 2004). The prevalence of 
subclinical rejection is maximal during the initial 3 months, progressively declines in the 
first year, but may persist in a small number of patients after the first year (Nankivell et al., 
2004b). According to the Banff criteria, approximately 1 out 3 subclinical rejection episodes 
are classified as being of interstitial acute rejection grade 1, and 2 out of 3 are classified as 
borderline changes (Nankivell et al., 2004d). 
The largest observational study to date of 961 renal transplant biopsies performed on 119 
consecutive simultaneous pancreas kidney transplant recipients reported an subclinical 
rejection prevalence of 60.8, 45.7, and 25.8 % at 1 month, 3 months, and 1 year, respectively 
(Nankivell et al., 2003). In renal recipients, the prevalence of subclinical rejection in 3-month 
protocol biopsies has been observed at between 23 and 43 %, but its difficulty to directly 
compare these results because of differences in histological interpretation, 
histocompatibility, patient selection, and immunosuppressive regimens (Nankivell et al., 
2001, Rush, DN  et al., 1994, 1995, Shapiro et al., 2001, Shishido et al., 2003). A prevalence of 
18 % at 3 months was reported in deceased donor kidney transplant recipients on 
Tacrolimus, azathioprine, and prednisone (Jurewicz, WA 1999), whereas in patients on 
tacrolimus, mycophenolate mofetil, and prednisone, the prevalence was only 2.6 % (Gloor et 
al., 2002). A recent randomized, multicenter study in renal transplant patients, considered to 
have a low risk profile of acute rejection, receiving tacrolimus, mycophenolate mofetil, and 
prednisone reported a low overall prevalence of subclinical rejection (4,6 %) (Rush, D 2007). 
Treatment of subclinical rejection in the biopsy arm of this study with high-dose steroids, 
however, did not result in beneficial outcomes, at least in the short term.  
6.2 Non Immune-dependent factors 
6.2.1 Donor age and cellular senescence 
It is generally accepted (Halloran et al., 1999, Basar et al., 1999, Oppenheimer et al., 2004) 
that increased donor age is associated with reduced actuarial graft survival, increased rate of 
delayed graft function, and earlier onset of chronic allograft nephropathy.  
In vitro studies have shown that cellular senescence can be categorized in either replicative, 
stress- or aberrant signaling-induced senescence (Itahana et al., 2004). 
Replicative senescence (so called “mitotic clock”) is associated with shortened telomeres in 
human (Harley et al., 1990). After a variable number of mitotic divisions, cells cannot pass 
from G1 to S phase of their cycle as a consequence of DNA loss corresponding to telomere 
shortening. 
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 A recent study (Westhoff et al., 2010) demonstrated in a telomere-deficient mouse model 
that telomere shortening was associated with reduced replicative capacities and a 
compromised ability of tubular cells to respond adequately to acute kidney injury. Although 
intriguing, the precise role of replicative senescence on the onset of chronic allograft 
nephropathy remain unclear.  
Stress- and aberrant signaling induced senescence is secondary to extrinsic stress and 
characterized by an increased expression of the cyclin-dependant kinase inhibitor p16, a cell 
cycle regulator, and the activation of the p53 pathway (Zindy et al., 1997). It has been shown 
that markers of the senescent cellular phenotype, such as p161NK4a, cyclogenase 1, or HSP 
A5, are overexpressed in allografts with chronic allograft nephropathy, suggesting the 
implication of some features of aging on graft impairment (Chkhotua et al., 2003. Melk et al.,  
2004). 
6.2.2 Brain death 
Brain death, in addition to other unspecific injuries of organs at the time of transplantation, 
is considered as the main reason for the superior clinical survival of living donor 
transplants, even when disadvantaged for human lymphocyte antigen compatibility (Gasser 
et al., 2000). 
It’s supposed that there’s, in kidneys from brain dead donor, an augmented inflammatory 
and dentritic cell response compared with kidneys from living donor (Timsit et al., 2010).  
6.2.3 Ischemia 
Consequences of ischemia/reperfusion injury correlate with chronic allograft nephropathy 
in clinical and experimental studies. A retrospective study based on the United Network for 
Organ Sharing database showed that prolonged cold ischemia was a significant risk factor 
for late allograft loss (Salahudeen et al., 2004). Increased graft immunogenicity, accelerated 
host immune responses, and fibrotic changes due to increased matrix synthesis are currently 
evocated as mechanisms correlating ischemia/reperfusion injury and chronic allograft 
nephropathy. 
Iischemia/reperfusion injury leads to an increased expression of both class I and class II 
major histocompatibility complex molecules in the allograft (Shoskeet al., 1996), as well as to 
accelerated dendritic cell differentiation and increased rates of acute rejection through either 
direct or indirect allorecognition (Ke et al., 2005). In addition, ischemia/reperfusion injury 
upregulates the expression of adhesion molecules and leukocyte recruitment in the graft 
leading to a sustained host immune response (Farhood et al., 1995, Osborn et al., 1990). 
6.2.4 Calcineurin Inhibitors nephrotoxicity 
Calcineurin inhibitors are pleomorphic nephrotoxins affecting every histological 
compartment of the transplanted kidney. The classical calcineurin inhibitors lesions (Benigni 
et al., 1999, Mihatsch et al. 1988, Davies et al., 2000) include de novo or increasing arteriolar 
hyalinosis and striped fibrosis, supported by microcalcification unrelated to other causes 
such as tubular necrosis and hyperparathyroidism (Gwinner et al., 2005). Ciclosporine A 
and Tacrolimus nephrotoxicity and increasingly common late after transplantation 
(Nankivell et al., 2003, Solez et al., 1998). Arteriolar hyalinosis is the most reliable diagnostic 
marker of calcineurin inhibitors nephrotoxicity (Solez et al., 1993). Confirmation of the 
diagnosis can be made by exclusion of donor hyalinosis detectable on implantation biopsy, 
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diabetes and hypertensive nephrosclerosis (distinguished by subendothelial hyalinosis, 
elastic lamina reduplication and medial hyperplasia in larger arteries (Mihatsch et al., 1988, 
Mihatsch et al., 1995). Severe arteriolar hyalinosis causes vascular narrowing and 
downstream ischemic glomerulosclerosis (Nankivell et al., 2004c)   
6.2.5 Recurrent glomerulonephritis 
Recurrent glomerulonephritis is diagnosed by exclusion of donor-transmitted disease and 
de novo glomerulonephritis, and currently accounts for 8.4% of allograft loss by 10 years in 
recipients with renal failure from glomerulonephritis (Briganti et al., 2002). The clinical 
course and severity of recurrent glomerular disease often recapitulates the patient’s native 
disease (Chadban et al., 2001) except for vasculitis or lupus nephritis, which are usually 
controlled by transplant immunosuppression. Focal segmental glomerulosclerosis (20–50% 
recurrence rates) and dense deposit disease (50–90% recurrence) have the worst prognosis; 
compared with membranous glomerulonephritis (29–50% recurrence), 
membranoproliferative glomerulonephritis type 1 (20–33% recurrence) or IgA nephropathy, 
which recurs in up to 58% but with less clinical impact (Chadban et al., 2001). Diabetic 
glomerulopathy can also recur in allografts, usually after many years.  
6.2.6 Infections 
Infectious diseases affect graft and patient survival and contribute to the development of  
chronic allograft nephropathy. This group of diseases includes nephropathy due to polyoma 
(BK) virus infection, direct and indirect effects of cytomegalovirus (CMV) infection, and 
bacterial infections. Rarer infections causes of chronic allograft nephropathy include 
cryoglobulinemia associated with hepatitis C, Epstein-Barr virus (EBV)-associated 
posttransplant lymphoproliferative disease (PTLD), and direct cytotoxicity from adenoviral 
infection or parvovirus B19. 
6.2.6.1 BK virus 
BK virus is an endemic polyoma virus of high prevalence, low morbidity, long latency and 
asymptomatic reactivation in immunocompentent individuals (Hirsch et al., 2003, Mannon 
et al., 2004). Prospective screening studies suggest that 50 % or more of patients develop BK 
viruria after transplantation, with a peak incidence in the first 3-12 months (Nickeleit et al.,  
2000b, White et al., 2008, Koukoulaki et al., 2009). However only 1-5 % of viruric patients go 
on to develop nephropathy (Smith et al., 2007, Kim et al. 2005). When BK virus-associated 
nephropathy (BKVAN) occurs, reported rates of graft loss have ranged from 10 to 80 % 
(Nickeleit et al., 2000a. Weiss et al., 2008). Although early reports suggested a link with 
Tacrolimus and mycophenolate-based regimens, it seems likely that the risk of BKVAN 
relates to the total burden of immunosuppression rather than to any specific drug 
(Rahamimov et al., 2003, Nickeleit et al., 2000a). 
Some authors reported that the injury of the renal allograft may have an important role in 
the pathogenesis of BKVAN (Drachenberg et al., 2005). The association found between 
human lymphocyte antigen mismatching and BKVAN supports the hypothesis (Awadalla et 
al., 2004).  
6.2.6.2 Cytomegalovirus 
The extent of the contribution of cytomegalovirus infection to chronic allograft nephropathy 
remains controversial. Cytomegalovirus infection has been shown to upregulate class I and 
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class II major histocompatibility complex molecules on T lymphocytes and renal 
parenchymal cells. This effect is likely to be a cytokine-mediated phenomenon because of 
upregulation of proinflammatory cytokines such as interferon-. The immediate early gene 
product of cytomegalovirus shares a sequence homology with human lymphocyte antigen 
DR (Beck et al., 1988). Cytomegalovirus infection also blocks p53 (an important cell cycle 
regulatory protein), which may inhibit apoptosis and promote graft vasculopathy (Garcia et 
al., 1997). Other potential indirect effects of cytomegalovirus include upregulation of 
antiendothelial antibodies contributing to graft vascular injury (Toyoda et al., 1997) and 
upregulation of adhesion molecules (Helantera et al., 2005), leading to enhanced adhesion of 
host, leukocytes to graft endothelium, and thereby promoting allograft injury and/or 
rejection. These indirect effects of cytomegalovirus are thought to affect graft survival 
principally through an increased risk of acute rejection. 
Although the combination of cytomegalovirus infection and acute rejection has an adverse 
effect on graft survival, whether cytomegalovirus infection contributes to graft failure, in the 
absence of acute rejection remains unclear. There is some evidence, mainly from animal 
models, suggesting a direct role for cytomegalovirus in mediating chronic allograft 
nephropathy.  
Cytomegalovirus infection has been shown to have both proinflammatory and profibrotic 
effects. In rodents, cytomegalovirus upregulates transforming growth factor-, platelet-
derived growth factor (which stimulates smooth muscle proliferation and fibroblast 
activity), and connective growth factor (Inkinen et al., 2001, Inkinen et al., 2003, Helantera et 
al., 2006). Clinical studies have demonstrated similar effects in man (Helantera et al., 2005). 
Cytomegalovirus infection is also known to induce macrophage scavenger receptors and 
phenotypic changes in vascular smooth muscle cells, which have been shown to contribute 
to vasculopathy in cardiac allografts (Carlquist et al., 2004).  
6.2.6.3 Urinary tract infection (UTI) 
Urinary tract infection is a common complication following renal transplantation (Prat et al.,  
1985, Abbott et al., 2001). Graft pyelonephritis is well recognized to cause graft dysfunction 
but the longer-term impact is less clear (Pelle et al., 2007). A review of US registry data 
suggested that late urinary tract infections are not benign but they may be associated with 
an increased risk of death and graft loss (Abbott et al., 2004). 
7. Management of chronic allograft nephropathy 
The multiple pathophysiological causes of injury suggest that no single action will suffice, 
but instead, it is more likely that several therapies and approaches will be needed to 
abrogate specific etiological insults. These may include multiple, specific antagonists which 
are targeted to drivers of fibrogenesis, and well as indirect therapy targeting control of 
hypertension, hyperlipemia, infections etc.  
7.1 Optimal immunosuppression 
Prevention of chronic allograft nephropathy is presently one of the main goals in renal 
transplantation for the improvement of kidney graft survival. Refinements in 
immunosuppressive protocols, both controlling alloimmune responses and avoiding 
calcineurin inhibitor nephrotoxicity, are mandatory.  
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Ideally, optimal immunosuppression to prevent chronic allograft nephropathy should 
provide low rates of acute rejection, low rates of subclinical rejection and should be based on 
non-nephrotoxic agents able to preserve renal function.  
Because calcineurin inhibitors nephrotoxicity, which seems common in the long term, has 
been considered as one of the main contributors to chronic allograft nephropathy, the 
prevention of chronic allograft nephropathy has been mainly attempted by 
reducing/avoiding the use of calcineurin inhibitors.  
Unfortunately, sparing calcineurin inhibitors strategies have been associated in several trials 
with an increased rate of acute rejection without significant improvement in renal function 
and no impact on graft survival. 
7.1.1 Mycophenolate mofetil (MMF)-based strategies 
The impact of avoiding of calcineurin inhibitors based on the immunosuppressive potency 
of mycophenolate mofetil was associated with controversial results. The first study 
conducted 10 years ago combined daclizumab, mycophenolate mofetil and steroids 
(Vincenti et al., 2001). The lack of calcineurin inhibitors resulted in an incidence of acute 
rejection of 48 % during the first 6 months after Tx, and at the end of the first year, more 
than 60 % of patients were on calcineurin inhibitors. The CAESAR study compared 2 arms. 
The first arm associated a triple therapy with conventional doses of cyclosporine A, 
mycophenolate mofetil and steroids and the second arm involving daclizumab, low-dose 
Cyclosporin A (trough level 50-100 ng/ml) and steroids with the discontinuation of 
cyclosporine A 6 months after the transplantation in this arm (Ekberg et al., 2007). Renal 
function was not significantly different between the 2 groups and there was a trend toward 
higher creatinine clearance in the low-dose cyclosporine A group. In contrast, the 
cyclosporine A withdrawal group did not have better renal function, and there was a 
rebound of acute rejection after cyclosporine A withdrawal that could have counterbalanced 
the renal benefits of cyclosporine elimination. Other studies with planned conversion from 
Calcineurin inhibitors to antimetabolites in de novo renal transplant recipients also resulted 
in an increase in acute rejection and biopsy-proven chronic rejection (Smak Gregoor et al., 
2000, 2002). In established stable patients treated with mycophenolate mofetil, 
discontinuation of cyclosporine A was followed by significant improvement in renal 
function at 1 year after this therapeutic change (Abramowicz et al, 2005), but with more 
patients losing their graft because of immune-mediated rejection at 5 years. In the 
Symphony study (Ekberg et al., 2007), the control arm with standard cyclosporine A and the 
low-dose cyclosporine A group had the same drug doses as in the CAESAR study. In 
addition, two more groups with reduced doses of Tacrolimus (target levels 3-7 ng/ml) or 
low sirolimus (target levels 4-8 ng/ml) were also enrolled in this large study of more than 
1600 patients. The mean calculated GFR was higher in patients receiving low-dose 
Tacrolimus (65,4 ml/min) than in the other three groups. The rate of biopsy-proven acute 
rejection (BPAR) was lower in patients receiving low-dose Tacrolimus (12,3 %) than in those 
receiving standard-dose cyclosporine A (25,8 %), low-dose cyclosporine A (24,0 %), or low-
dose sirolimus (37,2 %). Allograft survival differed significantly between the four groups 
(p=0.02) and was highest in the low-dose Tacrolimus group (94,2 %), followed by the low-
dose cyclosporine A group (93.1 %), the standard-dose cyclosporine A group (89.3 %), and 
the low-dose sirolimus group (89.3 %). The 3-year data of this study was published recently 
(Ekberg et al., 2009) and showed that the differences between treatment groups were often 
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no longer significant and renal function remained stable during the follow-up, suggesting 
that low-dose Tacrolimus with mycophenolate mofetil may avoid the negative effects on 
renal function commonly reported for standard calcineurin inhibitors regimes despite the 
potential patient’s selection and uncontrolled treatment modifications.  
7.1.2 Mammalian target of rapamycin (mTOR) inhibitor-based strategies 
The conversion from calcineurin inhibitors to mTOR inhibitors has been followed by 
variable success (Flechner et al., 2008). Conversion in cases with a significantly deteriorated 
renal function and proteinuria does no help to stabilize graft function. Indeed, all these 
concepts have been consolidated after a large prospective study with more than 800 
maintenance patients of conversion from calcineurin inhibitors to sirolimus (Schena et al., 
2009). In this trial, the efficacy and safety of converting maintenance renal transplant 
recipients from calcineurin inhibitors to sirolimus were evaluated. The primary end points 
were calculated GFR (stratified at baseline: 20-40 vs > 40 ml/min) and the cumulative rates 
of BPAR, graft loss, or death at 12 months. Enrollment in the 20-40 ml/min stratum was 
halted prematurely because of higher incidence of safety and points in the sirolimus 
conversion arm. The intent-to-treat analyses at 12 and 24 months showed no significant 
treatment difference in GFR in patients with baseline GFR higher than 40 ml/min stratum. 
On-therapy analysis of this cohort showed significantly higher GFR at 12 and 24 months 
after sirolimus conversion. Rates of BPAR, graft survival, and patient survival were similar 
between groups. Median urinary protein-to-creatinine ratios (UPr/Cr) were similar at 
baseline but significantly increased after sirolimus conversion. Post hoc analyses identified a 
subgroup of patients with baseline GFR > 40 ml/min and UPr/Cr ≤ 0.11, whose risk-benefit 
profile was more favorable after conversion than for the overall sirolimus conversion cohort. 
Thus, selection of suitable candidates is fundamental to get the profit of calcineurin 
inhibitors withdrawal with mTOR inhibitors. Consequent from the results of these trials on 
conversion from calcineurin inhibitors to mTOR inhibitors, it is generally accepted that 
elective and planned conversion may be the best approach to stabilize renal function.  
Switching immunosuppressive therapy from cyclosporine A-mycophenolate sodium (MPS) 
and therapy with everolimus-steroids at 6 months after renal transplantation is effective in 
preventing rejection with ameliorating renal function has been shown in a recent published 
interim analysis (Bemelman et al., 2009). 
It’s important to note that the immense majority of studies attempting de novo introduction 
or conversion to mTOR inhibitors have displayed significant discontinuation rates because 
of drug-related adverse effects. 
All the recent data suggest the importance of defining the right target levels for mTOR 
inhibitors and an adequate management of the overlapped toxicities of their use with 
antimetabolites.  
7.1.3 Belatacept-based strategies 
Belatacept is a second generation CTL4-Ig costimulator blocker with a high avidity for CD86 
and CD80 molecules and prevents T-cell activation (Larsen et al. 2005). This drug may be 
very interesting in the development of safe calcineurin inhibitors-free regimens to preserve 
renal function. Thus, in a phase II multicenter trial (Vincenti et al., 2005), therapy with 
cyclosporine A, MMF, and steroids plus basiliximab was compared with belatacept in two 
therapeutic regimens (more intensive (MI) and less intensive (LI)) depending on the dose 
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and frequency of belatacept administrations, in association with mycophenolate mofetil , 
steroids and basiliximab. Belatacept was used as in induction treatment since the first day of 
the transplantation and next given as a maintenance immunosuppressant. The belatacept-
treated arms, had a similar low incidence of acute rejection (18 and 19 %) at 6 months, 
compared with the cyclosporine A arm. This trial demonstrated, particularly at 12 months, 
lower incidence of chronic allograft nephropathy in protocol biopsies, better renal function 
in terms of measured GFR, and a more favorable cardiovascular risk profile in the 
costimulation blockade arm in comparison with the standard cyclosporine A and 
mycophenolate mofetil combination.  
This trial was followed by two phase III pivotal trials (Durrbach et al., 2010, Vincenti et al., 
2010) in patients receiving kidneys from conventional donors (BENEFIT) or extended 
criteria donors (BENEFIT-EXT). The Belatacept dose regimens, M1 and L1, were similar to 
those in phase II trials. The data of these 2 studies indicate that the renal benefits on function 
and structure are even more evident in optimal renal allografts, and that an induction and 
maintenance immunosuoppression based on belatacept may prevent long term graft 
deterioration. The incidence of acute rejection was similar across the groups and < 20 %, 
except for the MI in the BENEFIT study, suggesting the L1 regimen provides the best 
risk/benefit balance. Safety data from these studies have shown a higher incidence of post-
transplant lymphoproliferative disease in patients treated with belatacept, which was 
associated with the use of polyclonals, concomitant cytomegalovirus infection, and 
recipient’s seronegativity for Epstein-Barr virus.  
7.2 Non-immune interventions 
The discrepancy between significant improvements in the prevention of acute rejection and 
failure to ameliorate long-term outcomes suggests that non-immunological injuries may 
have an important role in the occurrence of chronic allograft nephropathy (Remuzzi et al., 
1998). Functional and structural changes of chronic renal allograft failure share similarities 
with those observed in other forms of chronic progressive kidney disease, in which decline 
of functioning nephron mass has been considered the key event. The existence of a single 
transplanted kidney supplies only half the number of nephron commonly available to a 
healthy subject. This implies workload per nephron to maintain body homeostasis (Brenner 
1985). Graft injury is the result of glomerular hypertension and hyperfiltration in surviving 
units, which in turn leads to graft injury (Azuma et al., 1997). Other aggressions act against 
transplanted kidney like surgical and ischemic injury, acute rejection, and chronic toxicity of 
calcineurin inhibitors (Naesens et al., 2009) and mTOR inhibitors (Tomlanovich et al., 2007).  
Strategies developed to preserve renal function in patients with chronic kidney disease are 
mandatory to improve renal graft outcome in the long term. 
7.2.1 Control of blood pressure 
Hypertension is frequent among renal transplant recipients and can be observed even 
starting from the first week after transplantation, mainly when doses of calcineurin 
inhibtors and steroids are elevated (Tedla et al. 2007). The prevalence of hypertension has 
changed from between 40 to 60 % in the pre-cyclosporine era to up to 80-90 % after the 
introduction of cyclosporine (Schwenger et al., 2001, Curtis et al., 1992).  
There are no randomized, controlled trials comparing different antihypertensive drugs or 
optimal BP goals in transplant recipients. On the basis of large clinical trials in non-
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transplant patients with or without kidney disease, the Kidney Disease Outcomes Quality 
Initiative (KDIGO) guidelines recommend BP goals of 125/75 mmHg for transplant 
recipients with proteinuria and 130/85 mmHg in the absence of proteinuria (Bakris et al., 
2000).  
The first step of treatment should be based on non-pharmacologic interventions such weight 
reduction, exercise, smoking cessation, and dietary sodium restriction. Reach target levels of 
BP and proteinuria required frequently a simultaneous initiation of non-pharmacologic and 
pharmacologic treatment (Svetkey et al., 2005). 
The choice of antihypertensive class depends on the individual patient. Calcium channel 
blockers can be used as first line therapy, especially in the early period of the transplantation 
because they are effective in counteracting the vasoconstrictive effect of high-dose 
calcineurin inhibitors (Harper et al., 1992). 
In opposition, in proteinuric chronic kidney disease patients, dihydropiridinic-calcium 
channel blocker has been associated with increased risk of renal disease and death (Wright 
Jr et al., 2002, Agodoa et al., 2001).  
The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in 
renal transplant recipients is now more frequent (Ram et al., 2008). This fact is due to the 
cardioprotective and renoprotective effects of renin-angiotensin system (RAS) blockade in 
the general population (Braunwald et al., 2004) and in patients with chronic kidney disease 
(Ruggenenti et al., 1997). 
A particular caution should be taken when using these agents in kidney transplant patients, 
as in the presence of artery stenosis of the graft the use of RAS inhibitors may dramatically 
increase the risk of kidney function impairment and hyperkalemia (Salzberg et al., 2007).  
However, the multifactorial nature of hypertension in transplanted patients often requires 
multiple drugs, including - or -blockers, centrally acting drugs, and diuretics (Ojo et al., 
2006).        
7.2.2 Proteinuria 
The prevalence of proteinuria in kidney transplant patients ranges between 10 and 25% 
(Kasiske, et al., 2000). The three most common causes of persistent proteinuria after kidney 
transplantation are chronic graft injury, recurrent glomerulonephritis, and drug related 
nephrotoxicity (Bear et al., 1988). Calcineurin inhibitors have been considered as the 
immunosuppressive drugs with the highest risk of nephrotoxicity. Recently, increasing 
evidence has suggested a potential nephrotoxicity also with mTOR inhibitors. Indeed, they 
have been associated with an increased risk of proteinuria, possibly resulting from a direct 
toxicity on glomerular and tubular epithelial cells (Tomlanovich et al., 2007).     
Proteinuria represents also a strong independent risk factor for graft loss (Bear et al., 1988). 
It’s a marker of progressive renal injury and contributes to progression of kidney 
dysfunction and fibrosis through aberrant proximal tubule protein uptake and direct 
tubular cell toxicity (Remuzzi et al., 2006).      
RAS inhibitors have been shown to be efficient in reducing proteinuria and progression of 
renal disease in experimental models of renal mass reduction and in patients with chronic 
nephropathies (Remuzzi et al., 2006). Interestingly, RAS inhibitor therapy may exert 
renoprotection independently from its effect on proteinuria. Indeed, AT1 receptors mediate 
inflammation and are involved in the profibrotic action exhibited by potent cytokines (Ruiz-
Ortega et al., 2006). Angiotensin II is also synthesized by the proximal renal tubule cells and 
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exhibits powerful hemodynamic and non-hemodynamic effects, all implicated in the 
progression of chronic kidney disease (Brewster et al., 2004).  
A recent analysis of 2031 patients, who received their first renal allograft at the Medical 
University of Vienna between 1990 and 2003, showed that RAS inhibitor therapy was 
associated with a significantly higher patient (74 versus 53%, P=0.001) and graft (59 versus 
43%, P¼0.002) survival at 10 years after transplant as compared with non-RAS inhibitor 
therapy (Heinze et al., 2006). This is at variance with a previous systematic review of 21 
studies consisting of 1549 patients on the effect of RAS inhibitor therapy after kidney 
transplantation that failed to show any beneficial effect on patient and graft survival over a 
median follow-up of 27 months (Hiremath et al., 2007). 
7.2.3 Hyperlipemia 
Hyperlipidemia is a frequent finding in kidney transplant recipients, affecting 60% of 
patients (Kasiske et al., 2000). Its pathogenesis is multifactorial and includes 
posttransplantation weight gain and the use of immunosuppressive drugs, such as mTOR 
inhibitors and steroids (Tsimihodimos et al., 2008). Particularly, higher triglyceride levels 
have been associated with poorer graft outcomes (Del Castillo et al., 2004). 
Therapeutic agents to control low-density lipoprotein cholesterol and triglycerides include 
statins as well as fenofibrates. Intriguingly, statins have been implicated as nephroprotective 
agents beyond their lipid-lowering ability because of their potential to regulate fibrogenic 
mechanisms, as well as their impact on endothelial dysfunction (Perico et al., 2008). The 
Assessment of Lescol in Renal Transplantation (ALERT) trial randomized 2102 renal 
transplant recipients with total cholesterol 156–351 mg/dl to fluvastatin or placebo over a 5-
year follow-up period. Treatment was safe and effective in lowering total and low-density 
lipoprotein cholesterol (Holdaas et al., 2003). Moreover, although the trial had insufficient 
power to detect a significant reduction in the primary end point of cardiac death, non-fatal 
myocardial infarction, or coronary intervention procedure, there was a significant 35% 
reduction in the secondary end point of cardiac death and non-fatal myocardial infarction 
with fluvastatin. The treatment, however, had no effect on graft survival or function. Yet, a 
recent randomized controlled study in 89 kidney transplant recipients showed a beneficial 
effect of fluvastatin (80 mg/day) over placebo on the incidence of transplant vasculopathy (7 
versus 33%; p=0.02) over 6 month followup (Seron et al., 2008). 
Attractively, experimental and clinical evidence suggest that statins may have an additive 
beneficial effect with RAS inhibitors on kidney graft outcomes (Perico et al., 2008). 
8. Immune monitoring and biomarkers to predict chronic allograft 
nephropathy 
Chronic allograft nephropathy continues to plague kidney allografts, in spite of potent 
immunosuppressive therapies. Both immune-dependent and -independent factors continue 
to contribute to failure. A number of promising observations made in human kidney 
recipients suggest unique protein and genetic signatures that may identify biomarkers of 
injury, as well as potential targets of therapy. Technical advances such as gene cDNA 
microarrays, proteomics and metabonomics will multiply the number of potential etiologies 
and mechanisms of chronic allograft nephropathy. Discrimination between clinically 
important versus statistically significant factors yielding small effects will be essential. 
www.intechopen.com
 
After the Kidney Transplant – The Patients and Their Allograft 
 
312 
Transcriptional changes may be detectable prior to histologically apparent fibrosis, and 
discrimination of inflammatory infiltrates according to the constellation of expressed genes, 
promises to both improve diagnoses and optimize treatment strategies (Mannon et al., 
2010). 
9. Conclusion 
Chronic kidney allograft abnormalities represent the effects of cumulative damage from a 
series of time-dependent stressors, which are combined with an allograft healing response 
and modified by immunosuppression. Early tubulointerstitial damage results from 
ischemia-reperfusion injury, acute tubular necrosis, acute and subclinical rejection and 
calcineurin inhibitor nephrotoxicity, superimposed upon donor abnormalities. Later, 
microvascular and glomerular Injury increases frequently as a result of calcineurin 
inhibitors nephrotoxicity, but also from hypertension, immune-mediated vascular 
hyperplasia, transplant glomerulopathy and occasionally from recurrent or de novo 
glomerulonephritis. Additional mechanisms of chronic allograft nephropathy include 
internal structural disruption of the kidney, cortical ischemia, inability to resolve chronic 
inflammation, senescence, cytokine excess, epithelial-to-mesenchymal induced fibrosis, 
hypertension and other stressors. Early detection (Fig 4) appears to be critical issue for this 
disorder. The role of protocol biopsy and management of subclinical rejection are under 
study. Treatment options are nonspecific and limited. Various immunosuppressive 
strategies avoiding or limiting calcineurin inhibitors, biologics and anti-proliferatives are 
under study. Despite marked improvements in short graft survival and reduction in acute 
rejection rates, long term graft function remains a critical issue. Current immunosuppressive 
regimens do not adequately address the causes of long-term allograft dysfunction and loss 
calcineurin inhibitors-sparing regimens are urgently required 
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